Nifty
Sensex
:
:
10265.65
33250.30
98.95 (0.97%)
301.09 (0.91%)

Pharmaceuticals & Drugs

Rating :
57/99   (View)

BSE: 532523 | NSE: BIOCON

521.70
-1.55 (-0.30%)
08-Dec-2017 | 3:52PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 524.00
  • 525.00
  • 518.15
  • 523.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 2066673
  • 10781.83
  • 525.60
  • 293.90

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 31,296.00
  • 69.72
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 32,554.20
  • 0.19%
  • 6.34

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 2.92%
  • 12.53%
  • FII
  • DII
  • Others
  • 1.36%
  • 2.46%
  • 20.06%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 17
Sep 16
Var%
Jun 17
Jun 16
Var%
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Net Sales
968.60
945.80
2.41%
933.70
982.40
-4.96%
931.10
978.80
-4.87%
1,037.60
836.40
24.06%
Expenses
786.30
705.80
11.41%
741.60
719.30
3.10%
743.60
765.70
-2.89%
761.50
647.30
17.64%
EBITDA
182.30
240.00
-24.04%
192.10
263.10
-26.99%
187.50
213.10
-12.01%
276.10
189.10
46.01%
EBIDTM
18.82%
25.15%
20.57%
26.78%
20.14%
21.77%
26.44%
22.61%
Other Income
50.80
38.40
32.29%
54.00
40.90
32.03%
43.20
24.70
74.90%
47.40
19.70
140.61%
Interest
13.80
6.50
112.31%
16.10
5.70
182.46%
5.00
1.40
257.14%
8.80
1.50
486.67%
Depreciation
93.60
68.30
37.04%
98.80
66.10
49.47%
72.50
62.80
15.45%
70.30
62.10
13.20%
PBT
125.70
203.60
-38.26%
131.20
232.20
-43.50%
153.20
442.00
-65.34%
244.40
145.20
68.32%
Tax
42.50
41.70
1.92%
37.60
55.20
-31.88%
10.30
58.20
-82.30%
54.40
24.10
125.73%
PAT
83.20
161.90
-48.61%
93.60
177.00
-47.12%
142.90
383.80
-62.77%
190.00
121.10
56.90%
PATM
8.59%
16.97%
10.02%
18.02%
15.35%
39.21%
18.19%
14.48%
EPS
1.15
2.44
-52.87%
1.36
2.78
-51.08%
2.13
6.01
-64.56%
2.86
1.72
66.28%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
2,367.82
1,608.67
1,053.79
Net Sales Growth
16.24%
8.34%
7.39%
15.77%
19.11%
15.53%
-23.73%
47.19%
52.66%
 
Cost Of Goods Sold
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
1,337.54
838.42
434.62
Gross Profit
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
1,030.27
770.25
619.17
GP Margin
62.82%
61.45%
59.36%
58.78%
57.98%
59.17%
59.83%
43.51%
47.88%
58.76%
Total Expenditure
2,911.60
2,579.60
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
1,896.33
1,285.31
757.67
Power & Fuel Cost
156.40
184.70
176.70
162.40
142.60
97.20
82.00
67.63
69.33
76.56
% Of Sales
4.02%
5.52%
5.72%
5.64%
5.74%
4.66%
4.54%
2.86%
4.31%
7.27%
Employee Cost
747.00
610.10
533.40
466.30
389.40
307.60
238.80
242.76
179.18
110.68
% Of Sales
19.20%
18.23%
17.26%
16.21%
15.67%
14.74%
13.22%
10.25%
11.14%
10.50%
Manufacturing Exp.
376.20
320.90
81.20
62.90
95.20
113.20
81.60
68.63
66.01
47.71
% Of Sales
9.67%
9.59%
2.63%
2.19%
3.83%
5.43%
4.52%
2.90%
4.10%
4.53%
General & Admin Exp.
21.70
42.60
165.70
131.80
122.20
93.20
82.40
79.09
56.15
38.71
% Of Sales
0.56%
1.27%
5.36%
4.58%
4.92%
4.47%
4.56%
3.34%
3.49%
3.67%
Selling & Distn. Exp.
107.40
100.80
108.70
118.90
99.60
89.40
62.40
56.49
47.67
32.53
% Of Sales
2.76%
3.01%
3.52%
4.13%
4.01%
4.28%
3.46%
2.39%
2.96%
3.09%
Miscellaneous Exp.
56.30
30.10
72.70
61.80
52.90
256.70
940.80
44.19
28.55
32.53
% Of Sales
1.45%
0.90%
2.35%
2.15%
2.13%
12.30%
52.09%
1.87%
1.77%
1.60%
EBITDA
979.50
767.80
695.80
687.10
539.00
277.20
-407.40
471.49
323.36
296.12
EBITDA Margin
25.17%
22.94%
22.52%
23.88%
21.69%
13.29%
-22.56%
19.91%
20.10%
28.10%
Other Income
157.10
79.20
53.10
55.90
56.70
309.40
1,035.50
37.02
64.55
38.88
Interest
26.00
29.30
8.90
1.70
8.10
12.40
24.30
16.89
17.66
10.18
Depreciation
277.20
248.70
221.00
203.60
179.30
175.80
156.70
140.14
110.25
93.92
PBT
833.40
569.00
519.00
537.70
408.30
398.40
447.10
351.47
260.00
230.91
Tax
161.60
142.20
95.70
106.90
97.50
55.90
72.10
48.67
11.84
12.89
Tax Rate
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
13.85%
10.50%
2.74%
PAT
595.80
528.70
497.40
413.80
508.90
341.60
367.50
293.25
93.84
463.91
PAT before Minority Interest
671.80
587.40
528.40
430.80
512.70
342.50
375.00
302.81
100.97
457.39
Minority Interest
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
-9.56
-7.13
6.52
PAT Margin
15.31%
15.79%
16.10%
14.38%
20.48%
16.37%
20.35%
12.38%
5.83%
44.02%
PAT Growth
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
25.32%
212.50%
-79.77%
 
Unadjusted EPS
31.18
28.04
24.87
21.09
25.99
17.27
18.79
15.08
4.83
46.39

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
1,757.85
1,510.74
1,484.15
Share Capital
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
50.00
Total Reserves
4,737.70
3,933.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
1,595.96
1,369.32
1,397.80
Non-Current Liabilities
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
564.44
570.54
301.55
Secured Loans
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
331.50
395.73
135.04
Unsecured Loans
3.90
11.40
11.40
25.80
40.00
60.50
65.80
182.11
128.18
120.01
Long Term Provisions
36.00
29.90
15.00
7.80
4.00
0.00
1.00
0.00
0.00
0.00
Current Liabilities
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
581.73
438.50
301.42
Trade Payables
739.70
609.80
429.30
347.20
345.50
347.80
296.50
230.86
208.55
172.38
Other Current Liabilities
698.20
527.10
706.20
612.30
313.10
269.20
375.90
260.05
148.42
57.64
Short Term Borrowings
97.20
394.90
261.00
243.50
84.80
187.30
247.40
0.00
0.00
0.00
Short Term Provisions
143.20
133.90
158.20
176.60
246.50
211.50
140.80
90.83
81.53
71.40
Total Liabilities
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55
2,079.80
Net Block
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
1,337.93
1,211.56
931.28
Gross Block
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
1,837.13
1,581.70
1,182.39
Accumulated Depreciation
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
499.20
370.14
251.11
Non Current Assets
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
1,460.60
1,422.68
1,101.10
Capital Work in Progress
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
75.52
172.02
138.21
Non Current Investment
188.80
26.80
0.00
64.50
64.50
64.20
60.90
47.16
39.10
31.60
Long Term Loans & Adv.
428.90
350.10
336.90
252.00
241.60
181.00
140.20
0.00
0.00
0.00
Other Non Current Assets
67.00
51.00
169.60
64.50
47.20
32.30
0.00
0.00
0.00
0.00
Current Assets
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
1,477.21
1,121.87
978.71
Current Investments
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
383.42
328.52
443.16
Inventories
635.30
542.40
452.70
376.60
398.40
378.30
413.70
371.64
319.18
178.98
Sundry Debtors
883.20
714.50
770.50
599.80
509.70
491.70
495.80
446.13
366.68
259.13
Cash & Bank
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
139.93
11.81
9.62
Other Current Assets
419.90
300.70
171.60
157.60
136.90
114.30
56.70
136.10
95.67
87.82
Short Term Loans & Adv.
267.80
227.10
75.80
81.80
81.40
37.10
20.20
120.28
95.05
82.76
Net Current Assets
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
895.48
683.37
677.28
Total Assets
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55
2,079.81

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Cash From Operating Activity
526.40
210.70
560.70
471.20
564.10
798.50
443.81
95.10
317.91
154.76
PBT
1,227.40
624.10
537.70
610.20
395.20
447.10
351.47
104.36
538.66
211.00
Adjustment
-409.40
74.00
134.00
147.30
144.80
163.50
159.65
135.89
-213.83
82.18
Changes in Working Capital
-44.80
-354.00
37.70
-192.30
98.00
269.20
-34.53
-128.21
17.34
-125.19
Cash after chg. in Working capital
773.20
344.10
709.40
565.20
638.00
879.80
476.60
112.04
342.18
167.99
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-246.80
-133.40
-148.70
-94.00
-73.90
-81.30
-32.79
-16.94
-24.27
-13.24
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-954.00
-508.70
-938.10
-375.80
-359.50
-314.50
-226.07
-232.19
-340.15
-191.17
Net Fixed Assets
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
-55.73
-84.56
-53.65
-118.55
Net Investments
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
-71.95
130.57
-430.24
92.04
Others
2,951.00
-779.30
-741.10
-200.00
-113.20
-112.27
-98.39
-278.20
143.74
-164.66
Cash from Financing Activity
1,086.70
186.20
426.00
-8.60
-186.30
-274.60
-85.21
136.93
23.22
43.09
Net Cash Inflow / Outflow
659.10
-111.80
48.60
86.80
18.30
209.40
132.53
-0.16
0.99
6.68
Opening Cash & Equivalents
462.60
557.00
474.00
369.00
359.00
139.90
11.81
9.62
8.63
1.95
Closing Cash & Equivalent
1,127.00
462.60
557.00
474.00
369.00
359.00
143.10
11.81
9.62
8.63

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
80.61
67.22
53.86
48.42
43.18
36.31
32.49
28.25
24.47
24.11
ROA
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
11.05%
4.37%
25.03%
ROE
15.15%
16.17%
17.22%
15.68%
21.50%
16.59%
20.58%
19.14%
6.93%
36.76%
ROCE
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
17.12%
6.92%
32.11%
Fixed Asset Turnover
0.89
1.05
1.09
1.12
1.11
1.06
0.97
1.42
1.19
0.96
Receivable days
74.35
80.16
80.09
69.48
72.22
84.37
93.20
60.98
69.27
95.54
Inventory Days
54.81
53.71
48.47
48.54
56.01
67.67
77.71
51.83
55.14
57.48
Payable days
79.07
68.27
58.15
55.73
65.24
70.25
70.62
41.52
51.80
83.01
Cash Conversion Cycle
50.09
65.60
70.42
62.29
62.99
81.79
100.29
71.30
72.61
70.02
Total Debt/Equity
0.48
0.61
0.35
0.30
0.10
0.12
0.17
0.30
0.36
0.18
Interest Cover
33.05
25.90
71.12
317.29
76.33
33.13
19.40
21.81
7.39
47.20

News Update


  • Biocon gets nod to transfer biosimilars business
    9th Dec 2017, 11:12 AM

    The special resolution was passed with 99.99 per cent of votes polled through postal ballot

    Read More
  • Biocon gets EMA regulator nod for proposed biosimilar trastuzumab, pegfilgrastim
    1st Dec 2017, 10:33 AM

    Pegfilgrastim is used to reduce the duration of neutropenia and the incidence of fever associated with neutropenia in adult patients treated with chemotherapy in certain types of cancer

    Read More
  • Biocon launches KRABEVA for treating several types of cancer in India
    23rd Nov 2017, 10:52 AM

    KRABEVA will help expand access to a world class, high quality biosimilar Bevacizumab for cancer patients in India

    Read More
  • Biocon receives EIR from USFDA for aseptic drug product facility
    20th Nov 2017, 08:47 AM

    The USFDA has classified the outcome of this inspection as VAI and the EIR states that the inspection is closed

    Read More
  • Biocon’s arm extends partnership with Bristol-Myers Squibb till 2026
    14th Nov 2017, 12:08 PM

    The expanded scope of partnership also includes addition of a new facility and ramping up the team of scientists working for it

    Read More
  • Biocon’s Mylan resubmits MAAs for Biosimilar Trastuzumab and Pegfilgrastim Dossiers
    7th Nov 2017, 09:10 AM

    This follows the earlier withdrawal of both applications in response to the audit of our aseptic drug product facility by the designated European authority

    Read More
  • Biocon reports 53% fall in Q2 consolidated net profit
    27th Oct 2017, 10:58 AM

    Total income of the company increased by 2.71% at Rs 1019.40 crore for quarter under review

    Read More
  • Biocon gets nod to transfer Biosimilars business to Biocon Biologics
    27th Oct 2017, 10:30 AM

    The company will transfer the same by way of a slump sale as ‘going concern’

    Read More
  • Biocon - Quarterly Results
    26th Oct 2017, 12:00 AM

    Read More
  • Biocon features in 'The Science Careers Top 20 Employers Survey 2017'
    25th Oct 2017, 09:16 AM

    The company has been recognized for being an innovative leader in the industry, having a clear vision and being socially responsible

    Read More
  • Biocon receives CRL from USFDA for proposed Biosimilar Pegfilgrastim
    10th Oct 2017, 09:06 AM

    The CRL relates to the pending update of the BLA with certain CMC data from facility requalification activities post recent plant modifications

    Read More
  • USFDA completes inspection at Biocon’s Vishakhapatnam facility
    18th Sep 2017, 16:01 PM

    The inspection was carried out between September 11, 2017 to September 15, 2017

    Read More
  • Biocon targeting $1 billion revenue by FY19
    11th Sep 2017, 12:00 PM

    The company is betting big on small molecules and generic formulations, biosimilars, branded formulations and research services

    Read More
  • Biocon’s arm receives EU GMP Compliance Certificate for insulin facility in Malaysia
    8th Sep 2017, 09:00 AM

    Biocon’s Malaysia facility was inspected by the EMA in April 2017

    Read More
  • Biocon, JDRF ink pact to support global multiple ascending dose study
    6th Sep 2017, 11:05 AM

    This collaboration with Biocon is a part of JDRF’s Industry Discovery and Development Partnership program

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.